Different regulatory effects of pentoxifylline on human T cell activation pathways

J Clin Immunol. 1997 May;17(3):247-52. doi: 10.1023/a:1027362629161.

Abstract

Pentoxifylline (PTX), a methylxanthine derivative, was examined for its effects on T cell proliferation and cytokine production stimulated by cross-linking anti-CD3 alone, anti-CD3 with PMA, anti-CD3 with anti-CD26, or anti-CD3 with anti-CD28 mAb, respectively. PTX at a 3.5 x 10(-5) M concentration significantly inhibited T cell proliferation and the production of tumor necrosis factor-alpha, interleukin-2, and interleukin-4. Moreover, this effect was selective for stimulation by cross-linking anti-CD3 with PMA, or anti-CD3 with anti-CD26, but not by cross-linking anti-CD3 with anti-CD28. These results suggest that the inhibitory effect of PTX on T cell activation involves the CD3 and CD26, but not the CD28 signal pathway.

Publication types

  • Comparative Study

MeSH terms

  • Cell Survival / drug effects
  • Cytokines / biosynthesis
  • Cytokines / drug effects
  • Humans
  • Lymphocyte Activation / drug effects*
  • Pentoxifylline / pharmacology*
  • T-Lymphocytes / cytology
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology*
  • Th1 Cells / drug effects
  • Th1 Cells / metabolism
  • Th2 Cells / drug effects
  • Th2 Cells / metabolism

Substances

  • Cytokines
  • Pentoxifylline